To see the other types of publications on this topic, follow the link: Mutation-specific.

Journal articles on the topic 'Mutation-specific'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Mutation-specific.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Erdem-Eraslan, Lale, Ya Gao, Nanne K. Kloosterhof, et al. "Mutation specific functions of EGFR result in a mutation-specific downstream pathway activation." European Journal of Cancer 51, no. 7 (2015): 893–903. http://dx.doi.org/10.1016/j.ejca.2015.02.006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kerem, Eitan. "Mutation specific therapy in CF." Paediatric Respiratory Reviews 7 (January 2006): S166—S169. http://dx.doi.org/10.1016/j.prrv.2006.04.213.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Alderton, Gemma K. "Cancer mutation-specific immune responses." Nature Reviews Cancer 14, no. 6 (2014): 387. http://dx.doi.org/10.1038/nrc3763.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Erdem-Eraslan, L., Y. Gao, N. Kloosterhof, et al. "CS-05 * MUTATION SPECIFIC FUNCTIONS OF EGFR RESULT IN A MUTATION-SPECIFIC DOWNSTREAM PATHWAY ACTIVATION." Neuro-Oncology 16, suppl 5 (2014): v52. http://dx.doi.org/10.1093/neuonc/nou242.5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Harper, P. S. "A specific mutation for Huntington's disease." Journal of Medical Genetics 30, no. 12 (1993): 975–77. http://dx.doi.org/10.1136/jmg.30.12.975.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Schmid, Fabian, Esther Glaus, Frans P. M. Cremers, Barbara Kloeckener-Gruissem, Wolfgang Berger, and John Neidhardt. "Mutation- and Tissue-Specific Alterations ofRPGRTranscripts." Investigative Opthalmology & Visual Science 51, no. 3 (2010): 1628. http://dx.doi.org/10.1167/iovs.09-4031.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

von Deimling, Andreas, Felix Sahm, and David Capper. "Mutation specific antibodies: tool or dinosaur?" Oncotarget 3, no. 9 (2012): 907–8. http://dx.doi.org/10.18632/oncotarget.633.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Heinen, Charlotte A., Aldo Jongejan, Peter J. Watson, et al. "A specific mutation inTBL1XR1causes Pierpont syndrome." Journal of Medical Genetics 53, no. 5 (2016): 330–37. http://dx.doi.org/10.1136/jmedgenet-2015-103233.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Turchini, John, Juliana Andrici, Loretta Sioson, et al. "NRASQ61R Mutation-specific Immunohistochemistry is Highly Specific for Either NRASQ61R or KRASQ61R Mutation in Colorectal Carcinoma." Applied Immunohistochemistry & Molecular Morphology 25, no. 7 (2017): 475–80. http://dx.doi.org/10.1097/pai.0000000000000333.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ardicli, D., B. Konuskan, G. Haliloglu, M. Alikasifoglu, and H. Topaloğlu. "Nonsense mutation dystrophinopathy: How mutation-specific treatments changed our clinical practice?" Neuromuscular Disorders 25 (October 2015): S253. http://dx.doi.org/10.1016/j.nmd.2015.06.247.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Drake, John W. "Contrasting Mutation Rates from Specific-Locus and Long-Term Mutation-Accumulation Procedures." G3: Genes|Genomes|Genetics 2, no. 4 (2012): 483–85. http://dx.doi.org/10.1534/g3.111.001842.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Kitamura, Atsuko, Waki Hosoda, Eiichi Sasaki, Tetsuya Mitsudomi, and Yasushi Yatabe. "Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer." Clinical Cancer Research 16, no. 13 (2010): 3349–55. http://dx.doi.org/10.1158/1078-0432.ccr-10-0129.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

CHIAL1, H. "Megacolon associated with a specific genetic mutation." American Journal of Gastroenterology 96, no. 9 (2001): S188. http://dx.doi.org/10.1016/s0002-9270(01)03374-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Ambrosini-Spaltro, Andrea, Nicoletta Campanini, Beatrice Bortesi, et al. "EGFR Mutation-specific Antibodies in Pulmonary Adenocarcinoma." Applied Immunohistochemistry & Molecular Morphology 20, no. 4 (2012): 356–62. http://dx.doi.org/10.1097/pai.0b013e31823e064b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Willyard, Cassandra. "Companies compete over mutation-specific melanoma drugs." Nature Medicine 17, no. 3 (2011): 268. http://dx.doi.org/10.1038/nm0311-268a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Sanders, D. B., and P. M. Farrell. "Transformative mutation specific pharmacotherapy for cystic fibrosis." BMJ 344, jan09 1 (2012): e79-e79. http://dx.doi.org/10.1136/bmj.e79.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Møller, P., Å. Borg, G. Evans, et al. "Mutation-Specific Survival of Inherited Breast Cancer." Disease Markers 15, no. 1-3 (1999): 205. http://dx.doi.org/10.1155/1999/902648.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Gusmão, L., P. Sánchez-Diz, F. Calafell, et al. "Mutation rates at Y chromosome specific microsatellites." Human Mutation 26, no. 6 (2005): 520–28. http://dx.doi.org/10.1002/humu.20254.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Flanigan, Kevin M. "Mutation-specific database and bioinformatics resource forDMD." Human Mutation 30, no. 6 (2009): v. http://dx.doi.org/10.1002/humu.21051.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Ritterhouse, Lauren L., and Justine A. Barletta. "BRAF V600E mutation-specific antibody: A review." Seminars in Diagnostic Pathology 32, no. 5 (2015): 400–408. http://dx.doi.org/10.1053/j.semdp.2015.02.010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Ellegren, Hans, and Anna-Karin Fridolfsson. "Sex-Specific Mutation Rates in Salmonid Fish." Journal of Molecular Evolution 56, no. 4 (2003): 458–63. http://dx.doi.org/10.1007/s00239-002-2416-z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Ronzier, Elsa, Alessandra Matavel, Yitschak Biton, et al. "Mutation-Specific Cardiac Risk Assessment in LQT3." Biophysical Journal 110, no. 3 (2016): 34a. http://dx.doi.org/10.1016/j.bpj.2015.11.250.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Capper, David, Hanswalter Zentgraf, Jörg Balss, Christian Hartmann, and Andreas von Deimling. "Monoclonal antibody specific for IDH1 R132H mutation." Acta Neuropathologica 118, no. 5 (2009): 599–601. http://dx.doi.org/10.1007/s00401-009-0595-z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Partridge, M., G. Emilion, M. Falworth, et al. "Patient-specific mutation databases for oral cancer." International Journal of Cancer 84, no. 3 (1999): 284–92. http://dx.doi.org/10.1002/(sici)1097-0215(19990621)84:3<284::aid-ijc15>3.0.co;2-y.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Byers, Richard, Jason L. Hornick, Eleni Tholouli, Jeffery Kutok, and Scott J. Rodig. "Detection of IDH1 R132H Mutation in Acute Myeloid Leukemia by Mutation-specific Immunohistochemistry." Applied Immunohistochemistry & Molecular Morphology 20, no. 1 (2012): 37–40. http://dx.doi.org/10.1097/pai.0b013e31822c132e.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Nowacki, P. "PAH Mutation Analysis Consortium Database: 1997. Prototype for relational locus-specific mutation databases." Nucleic Acids Research 26, no. 1 (1998): 220–25. http://dx.doi.org/10.1093/nar/26.1.220.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Susanti, Susanti, Wakkas Fadhil, Shamayal Murtaza, et al. "Positive association of PIK3CA mutation with KRAS mutation but not BRAF mutation in colorectal cancer suggests co-selection is gene specific but not pathway specific." Journal of Clinical Pathology 72, no. 3 (2018): 263–64. http://dx.doi.org/10.1136/jclinpath-2018-205483.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Gupta, Archana A., Pooja Jaisinghani, Narayanasamy Priyadharshini, Chandini Rajkumar, and Shivaranjhany Sivakumar. "Need for mutation-specific treatment strategy in cancer." Journal of Oral Disease Marker 2, no. 1 (2018): 29. http://dx.doi.org/10.15713/ins.jodm.16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Chan, AdenKa-Yin, RikiRui-Qi Zhang, Abudumijiti Aibaidula, et al. "BRAF mutation marks out specific subgroups of glioma." Glioma 1, no. 5 (2018): 168. http://dx.doi.org/10.4103/glioma.glioma_33_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Massey, Ruth C., and Angus Buckling. "Environmental regulation of mutation rates at specific sites." Trends in Microbiology 10, no. 12 (2002): 580–84. http://dx.doi.org/10.1016/s0966-842x(02)02475-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Tomaselli, Pedro J., Alejandro Horga, Alexander M. Rossor, et al. "IGHMBP2 mutation associated with organ-specific autonomic dysfunction." Neuromuscular Disorders 28, no. 12 (2018): 1012–15. http://dx.doi.org/10.1016/j.nmd.2018.08.010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Melief, Cornelis J. M. "Mutation-Specific T Cells for Immunotherapy of Gliomas." New England Journal of Medicine 372, no. 20 (2015): 1956–58. http://dx.doi.org/10.1056/nejmcibr1501818.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Greenberg, Eyal, Gideon Rechavi, Ninette Amariglio, et al. "Mutagen-Specific Mutation Signature Determines Global microRNA Binding." PLoS ONE 6, no. 11 (2011): e27400. http://dx.doi.org/10.1371/journal.pone.0027400.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Cotton, Richard G. H. "MITOMASTER: A model for Locus-Specific Mutation Databases." Human Mutation 30, no. 1 (2009): vii. http://dx.doi.org/10.1002/humu.20963.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Cruts, Marc, Jessie Theuns, and Christine Van Broeckhoven. "Locus‐specific mutation databases for neurodegenerative brain diseases." Human Mutation 33, no. 9 (2012): 1340–44. http://dx.doi.org/10.1002/humu.22117.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Malling, H. V. "Genetic heterogeneity in mammalian specific-locus mutation systems." Environmental and Molecular Mutagenesis 26, no. 3 (1995): 187–88. http://dx.doi.org/10.1002/em.2850260302.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Gonin-Laurent, Nathalie, Anne Gibaud, Mathilde Huygue, et al. "Specific TP53 mutation pattern in radiation-induced sarcomas." Carcinogenesis 27, no. 6 (2006): 1266–72. http://dx.doi.org/10.1093/carcin/bgi356.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Grandchamp, B., C. Picat, V. Mignotte, et al. "Tissue-specific splicing mutation in acute intermittent porphyria." Proceedings of the National Academy of Sciences 86, no. 2 (1989): 661–64. http://dx.doi.org/10.1073/pnas.86.2.661.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Clancy, Colleen E., and Xander H. T. Wehrens. "Mutation-specific effects of lidocaine in Brugada syndrome." International Journal of Cardiology 121, no. 3 (2007): 249–52. http://dx.doi.org/10.1016/j.ijcard.2007.05.060.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Jabbar, Kausar J., Rajalakshmi Luthra, Keyur P. Patel, et al. "Comparison of Next-generation Sequencing Mutation Profiling With BRAF and IDH1 Mutation-specific Immunohistochemistry." American Journal of Surgical Pathology 39, no. 4 (2015): 454–61. http://dx.doi.org/10.1097/pas.0000000000000325.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Jo, Yun Sol, Min Sung Kim, Nam Jin Yoo, and Sug Hyung Lee. "Absence of PRKD1 Mutation, a Salivary Tumor-Specific Mutation, in Solid Tumors and Leukemias." Pathology & Oncology Research 22, no. 1 (2015): 231–32. http://dx.doi.org/10.1007/s12253-015-0001-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Capper, David, Matthias Preusser, Antje Habel, et al. "Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody." Acta Neuropathologica 122, no. 1 (2011): 11–19. http://dx.doi.org/10.1007/s00401-011-0841-z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Rizzolo, Piera, Valentina Silvestri, Virginia Valentini, et al. "Gene-specific methylation profiles in BRCA-mutation positive and BRCA-mutation negative male breast cancers." Oncotarget 9, no. 28 (2018): 19783–92. http://dx.doi.org/10.18632/oncotarget.24856.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Uguen, A., M. Talagas, M. Braekeleer, and P. Marcorelles. "A Place for BRAFV600E Mutation-specific Immunohistochemistry Alongside Cell-free DNA Mutation Detection in Melanoma." Acta Dermato Venereologica 96, no. 3 (2016): 426–27. http://dx.doi.org/10.2340/00015555-2286.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Chear, Chai Teng, Revathy Nallusamy, Scott W. Canna, et al. "A novel de novo NLRC4 mutation reinforces the likely pathogenicity of specific LRR domain mutation." Clinical Immunology 211 (February 2020): 108328. http://dx.doi.org/10.1016/j.clim.2019.108328.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Pinto, Nádia, Leonor Gusmão, and António Amorim. "Mutation and mutation rates at Y chromosome specific Short Tandem Repeat Polymorphisms (STRs): A reappraisal." Forensic Science International: Genetics 9 (March 2014): 20–24. http://dx.doi.org/10.1016/j.fsigen.2013.10.008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Baaj, Yasser, Corinne Magdelaine, Virginie Ubertelli, et al. "A highly specific microarray method for point mutation detection." BioTechniques 44, no. 1 (2008): 119–26. http://dx.doi.org/10.2144/000112630.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Matsubara, Yoichi. "Mutation detection by sequencing and TaqMan-allele specific amplification." SEIBUTSU BUTSURI KAGAKU 45, no. 1 (2001): 9–10. http://dx.doi.org/10.2198/sbk.45.9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Chan, Nelson C. N., Chi-Keung Cheng, Kelvin C. F. Chan, et al. "Distinctive regional-specific PROS1 mutation spectrum in Southern China." Journal of Thrombosis and Thrombolysis 46, no. 1 (2018): 120–24. http://dx.doi.org/10.1007/s11239-018-1660-z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Baer, Constance Regina, Niroshan Nadarajah, Yasunobu Nagata, et al. "Myelodysplastic Syndrome Patients Show Mutation-Specific DNA Methylation Patterns." Blood 126, no. 23 (2015): 1646. http://dx.doi.org/10.1182/blood.v126.23.1646.1646.

Full text
Abstract:
Abstract Introduction: Myelodysplastic syndromes (MDS) are characterized by recurrent mutations, which contribute to the classification of patients into prognostic subgroups. Besides genetic lesions, MDS cells show aberrant DNA methylation, which is used as a therapeutic target for pharmacological DNA demethylation. Genetic and epigenetic aberrations are tightly linked: The most frequently mutated genes in MDS are key players in epigenetic pathways, including DNMT3A and TET2, which directly regulate DNA methylation. Additionally, other epigenetic master regulators (EZH2 and ASXL1) are recurren
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!